Chimerix (NASDAQ: [[ticker:CMRX]]) has appointed Allen Melemed as its new chief medical officer. He comes to the Durham, NC-based drug developer after more than 20 years at Eli Lilly (NYSE: [[ticker:LLY]]), where he was most recently distinguished medical fellow and senior director of regulatory affairs for oncology in North America. Chimerix is preparing to start Phase 3 testing of dociparstat sodium in patients with acute myeloid leukemia. The company is also evaluating the drug in a Phase 2/3 study as a potential treatment for acute lung injury in COVID-19 patients.
